CME
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
August 18, 2023
Host: Omid Hamid, MD
Host: Sapna Patel, MD
Host: Ryan Sullivan, MD
Host: Jeffrey S. Weber, MD, PhD
Approximately 50 - 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!